Meet Radiation Oncologist Jonathan Yang


Jonathan Yang is a radiation oncologist who specializes in treating tumors of the central nervous system. This includes primary brain tumors, metastatic brain tumors and spine tumors.

Show transcript

Hello, how are you? Nice to see you.

I hope that patients can feel that “Yes, we are dealing with the difficult diagnosis; however, there are options.”

My name is Jonathan Yang. I am the Director of Metastatic Disease in the Department of Radiation Oncology at Memorial Sloan Kettering.

I’m gonna do a quick exam.

I specialize in providing treatments that are very directed and very focused to specific sites. And this can be often achieved with stereotactic radiosurgery or stereotactic body radiotherapy. I also specialize in proton therapy.

The way that I utilize proton therapy is that I use it to treat a larger area, because I want to maximize radiation dose to the larger area while sparing the tissue around that area. With stereotactic radiosurgery or stereotactic body radiotherapy, what we’re doing is that we’re actually treating a smaller area and therefore being able to concentrate that radiation dose better in that tumor.

There are several reasons that a patient may choose to come to MSK for the treatment of their metastasis.

Great, let’s take a look at her MRI.

One of the main reasons is because in Radiation Oncology we have a dedicated program for it, which is very unique in this country.

Other reasons that a patient may choose to come to MSK is because we’re doing very innovative treatments for these patients through innovative research and protocols that they may not have the ability to participate in elsewhere.

As we continue to advance our different type of treatments for patient with metastasis, we’re going to see a continuing growing patient population that's living with metastatic cancer — which really calls for a dedicated approach for these patients. And I want to be part of that.

I will see you in a couple of months.

I do think MSK is a pioneer in this, and we’re making great strides — and I think it’s very exciting.